TPST · Tempest Therapeutics, Inc.

Tempest Therapeutics Inc Is A Late-Stage Develpment Biotechnology Company Developing Small Molecule Therapeutics To Treat Cancer Through Mechanisms That Directly Kill Tumor Cells And Activate Tumor-Specific Immunity. Its Clinical-Stage Therapeutic Product Candidates Are Tpst-1120 And Tpst-1495 Which Are Clinical-Stage Molecules Designed To Inhibit Their Respective Targets. Company'S Small-Molecule Product Candidate, Amezalpat (Previously Known As Tpst-1120), Has Completed A Phase 2 Study In First-Line Hepatocellular Carcinoma And The Second Small-Molecule Product Candidate Is Tpst-1495, Plans To Initiate A Phase 2 Study For In Familial Adenomatous Polyposis.